Stocks and Investing
Stocks and Investing
Fri, May 27, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Thu, May 26, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Charles Duncan Maintained (STOK) at Buy with Decreased Target to $38 on, May 26th, 2022
Charles Duncan of Cantor Fitzgerald, Maintained "Stoke Therapeutics, Inc." (STOK) at Buy with Decreased Target from $68 to $38 on, May 26th, 2022.
Charles has made no other calls on STOK in the last 4 months.
There are 2 other peers that have a rating on STOK. Out of the 2 peers that are also analyzing STOK, 0 agree with Charles's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Charles
- Greg Harrison of "B of A Securities" Maintained at Strong Buy with Decreased Target to $40 on, Wednesday, March 16th, 2022
- Suji Jeong of "Jefferies" Initiated at Strong Buy and Held Target at $50 on, Monday, January 31st, 2022
Contributing Sources